GSK 2618960

Drug Profile

GSK 2618960

Alternative Names: 2618960; GSK2618960

Latest Information Update: 20 Apr 2016

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Monoclonal antibodies
  • Mechanism of Action Interleukin 7 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Sjogren's syndrome
  • Discontinued Multiple sclerosis

Most Recent Events

  • 01 Sep 2015 GlaxoSmithKline completes a phase I trial in healthy volunteers in the UK (NCT02293161)
  • 30 Nov 2014 GlaxoSmithKline initiates a phase I trial in Healthy volunteers in United Kingdom (NCT02293161)
  • 17 Nov 2014 GlaxoSmithKline plans a phase I trial in Healthy volunteers in United Kingdom (NCT02293161)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top